Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATITUDE-PsA-3002 phase 3 study of zasocitinib in active psoriatic arthritis
jRCT2031250061Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of zasocitinib in psoriatic arthritis (PsA) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of participants achieving ACR20 response at Week 16 for zasocitinib Dose A and Dose B compared to placebo. Started Mar 2025; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2031250061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250061.